用于疫苗接种目的的mRNA负载的聚（β-氨基酯）纳米颗粒的合成和表征

Executive Industry Relevance

This protocol enables the rapid formulation of mRNA-loaded polymeric nanoparticles for vaccine development, addressing the instability and rapid clearance of naked mRNA. The versatility of poly(beta aminoester) polymers allows encapsulation of diverse nucleic acids, supporting both prophylactic and therapeutic applications. Lyophilization enhances storage stability, reducing distribution costs and enabling scalable manufacturing for oncology and infectious disease pipelines.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses by delivering mRNA encoding tumor-associated antigens or immunomodulatory proteins.
• Operational Value: Supports functional target validation through efficient transfection of dendritic cells, demonstrated by upregulation of CD11b and CD86 markers.
• Predictive Value: Provides quantitative transfection data via flow cytometry to assess antigen expression and immune activation, informing go/no-go decisions.

Screening & Assay Development

• Scientific Value: Generates reproducible nanoparticle formulations with consistent size (~50 nm) and polydispersity, confirmed by physicochemical characterization and TEM.
• Operational Value: Uses simple pipetting and vortexing steps, enabling high-throughput preparation and lyophilization for long-term storage.
• Assay Readiness: Produces mRNA-loaded nanoparticles capable of transfecting HEK293 and JAWS II cells, supporting standardized immunoassay development.

Translational & Preclinical Research

• Translational Continuity: Bridges discovery to preclinical by enabling mRNA delivery that activates dendritic cells, a key step in cancer immunotherapy and vaccine efficacy.
• Disease-Relevant System: Demonstrates applicability to ovalbumin mRNA, a model antigen, supporting adaptation to tumor-associated antigens for cancer vaccinology.
• Risk Mitigation: Lyophilized nanoparticles show no significant change in size or PDI, ensuring batch consistency and reducing formulation-related failure risk.

Pipeline & Workflow Integration

The method fits within the early discovery to preclinical continuum, enabling mRNA-based antigen delivery for immune activation studies prior to lead optimization.

• Discovery Biology: Facilitates hypothesis testing by delivering mRNA encoding antigens or cytokines to assess immune cell activation in vitro.
• Screening: Delivers standardized, lyophilizable nanoparticles for reproducible transfection across cell types, supporting assay scalability.
• Analytics: Provides flow cytometry readouts for % GFP+ cells and marker expression (CD11b, CD86), enabling quantitative comparison of formulation efficacy.
• Translational Research: Supports continuity from in vitro dendritic cell activation to preclinical immune response modeling, particularly in cancer vaccine development.
• Enterprise Reuse: Platform adaptability to various mRNAs (e.g., GFP, ovalbumin, tumor antigens) allows reuse across multiple projects without reformulation.

Operational & Enterprise Impact

• Scientific Value: Reduces mechanistic ambiguity in mRNA delivery by providing a characterized, stable nanoparticle system with proven transfection efficiency.
• Operational Value: Simple preparation (pipetting, vortexing) and lyophilization enhance lab-to-lab reproducibility and reduce technical variability.
• Strategic Value: Enables rapid prototyping of mRNA vaccines, accelerating go/no-go decisions and reducing investment in ineffective candidates.
• Portfolio Impact: Supports risk-adjusted prioritization by generating early efficacy data on antigen expression and dendritic cell maturation.

Implementation Considerations

• Requires expertise in nucleic acid handling, nanoparticle formulation, and flow cytometry.
• Needs access to vortexers, thermoblocks, lyophilizers, fluorescence microscopes, and flow cytometers.
• Standardization across teams requires consistent polymer:mRNA ratios and incubation conditions (25°C for 30 min).
• Adaptation to different mRNAs may require optimization of concentration and incubation time, though encapsulation efficiency remains consistent across transcripts.
• Lyophilization protocol includes freezing at -80°C, primary drying, and storage at -20°C to prevent rehydration and maintain nanoparticle integrity.

Biopharma FAQs